Chemotherapy-associated ovarian damage comprises not only infertility but also premature menopause. The latter has been reported as a consequence of alkylating chemotherapy for breast cancer or Hodgkin's lymphoma (HL). In this study, we assessed the long-term impact of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimens on ovarian function in patients with aggressive non-Hodgkin lymphoma (NHL).
Long-term survivors after CHOP or CHOP plus etoposide (CHOEP) treatment within the Mabthera International Trial (MInT) or the NHL B1 trial of the German NHL Study Group were requested to respond to a questionnaire and to consent to blood sampling for hormone assessment.
A total of 46 of 81 contacted patients with a median age of 32.5 years at the time of enrolment into the aforementioned clinical trials responded to the questionnaire. The median follow-up after completion of treatment was 14 years. Last menstrual bleeding occurred significantly earlier in patients compared to the general population (47 versus 51 years, P<0.0001). In comparison to the distribution of menopausal symptoms in the general population, the percentage of women with moderate or severe menopausal symptoms was increased. In 23 patients who agreed to participate in laboratory analyses, anti-Muller-hormone (AMH) as a marker of ovarian reserve was decreased when compared to correspondent age groups of the general population.
Although most female patients regain fertility after CHOP-like chemotherapy, late ovarian impairment occurs frequently. Therefore awareness of such delayed side effects at the time of counseling is of importance.
Pharmacology, Toxicology and Pharmaceutical Science
3
6%
Nursing and Health Professions
2
4%
Social Sciences
2
4%
Chemical Engineering
1
2%
Other
5
10%
Unknown
20
40%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2015.
All research outputs
#16,720,137
of 25,371,288 outputs
Outputs from Annals of Oncology
#6,063
of 7,854 outputs
Outputs of similar age
#159,199
of 279,023 outputs
Outputs of similar age from Annals of Oncology
#90
of 138 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,854 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,023 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 138 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
